

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
25 September 2014 @ 09:00 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 07:45 AM–9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the Defense Health Agency Formulary Management Branch will present relative clinical and cost- effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The P&T Committee made recommendations for the following drug classes during the August 2014 meeting:

- ***Designated Newly-Approved Drugs***
 - ***Non-Insulin Diabetes Drugs: Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA)—albiglutide injection (Tanzeum)***
 - ***Attention Deficit Hyperactivity (ADHD) Drugs—methylphenidate extended release oral suspension (Quillivant XR)***
- ***Drug Class Reviews:***
 - ***Targeted Immunomodulatory Biologics (TIBs)***
- ***Utilization Management Issues***
 - ***Prior Authorization Criteria***
 - ***Insulin Delivery Device: Valeritas System (V-Go)***
 - ***Newer Sedative Hypnotics: Tasimelteon (Hetlioz)***
 - ***Metastatic Melanoma Drugs: Trametinib (Mekinist) and Dabrafenib (Tafinlar)***
 - ***Seizure Medications: Topiramate extended release capsules (Trokendi XR and Qudexy XR)***
- **Section 703 Review**
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.